PATENT
ATTORNEY DOCKET NO. 051538-5001-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Kevan M. SHOKAT	)	
	)	
Prior Application No.: 09/480,993	)	Group Art Unit: 1651
	)	
Prior Application Filed: January 11, 2000	)	Examiner: Jon Weber, Ph.D.
	)	
For: HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF	)	

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application.

Copies of the listed documents are attached. Applicant respectfully requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP



Sally P. Teng
Reg. No. 45,397

Dated: January 15, 2002
Customer No. 09629
MORGAN, LEWIS & BOCKIUS LLP
1800 M Street, N.W.
Washington, D.C. 20036-5869
(202) 467-7000

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) PTO Form 1449	Attorney Docket No. 051538-5001-01	Application No. not yet assigned Divisional of 09/480,993
	Applicants: Kevan M. SHOKAT	
	Filing Date: 01/15/02	Group Art Unit: 1651

U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
		5,593,997	01/14/97	Dow et al.	514	258	05/23/95

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Bishop *et al.*, 1999, Acquisition of Inhibitor-Sensitive Protein Kinases Through Protein Design. *Pharmacol. Ther.*, 82, 337-346.
	Bishop *et al.*, 1998, Design of Allele-Specific Inhibitors to Probe Protein Kinase Signaling. *Current Biology*, 8, 257-266.
	Bishop *et al.*, 1999, Generation of Monospecific Namomolar Tyrosine Kinase Inhibitors via a Chemical Genetic Approach. *J. Am. Chem. Soc.*, 121, 627-631.
	Bolen *et al.*, 1992, The Src Family of Tyrosine Protein Kinases in Hemopoietic Signal Transduction. *FASEB*, 6: 3403.
	Brown *et al.*, 1996, Regulation, Substrates and Functions of Src. *Biochimica Biophys. Acta* 1287, 121-149.
	Brugge *et al.*, 1977, Identification of a Transformation-Specific Antigen Induced by an Avian Sarcoma Virus. *Nature*, 269:346.
	Cohen *et al.*, 1995, Modular Binding Domains in Signal Transduction Proteins. *Cell*, 80: 237.
	Espinoza *et al.*, 1994, Cell Cycle Control by a Complex of the Cyclin HCS26 (PCL1) and the Kinase PHO85. *Science* 266, 1388-1391.
	Faltynek *et al.*, 1995, Damnacanthal is a Highly Potent, Selective Inhibitor of $p56^{lck}$ Tyrosine Kinase Activity. *Biochemistry*, 34:12404.
	Hanefeld *et al.*, 1996, One-Pot Synthesis of Tetrasubstituted pyrazoles -- Proof of Regiochemistry. *J. Chem. Soc., Perkin Trans* 1: 1545-1552.
	Hanke *et al.*, 1996, Discovery of a Novel, Potent, and Src Family-Selective Tyrosine Kinase Inhibitor. *J. Biol. Chem.* 271: 695.
	Hanks *et al.*, 1991, Protein Kinase Catalytic Domain Sequence Database: Identification of Conserved Features of Primary Structure and Classification of Family Members. *Meth. Enzymol.* 200, 38-81.
	Hunter *et al.*, 1987, A Thousand and One Protein Kinases. *Cell*, 50: 823.
	Hunter *et al.*, 1995, Protein Kinases and Phosphatases: The Yin and Yang of Protein Phosphorylation and Signaling. *Cell*, 80: 225.
	International Search Report mailed July 19, 2000
	Kelly, 1991. Calmodulin-Dependent Protein Kinase II. *Mol. Neurobiol.* 5, 153-177.
	Laneuville, 1995. Abl Tyrosine Protein Kinase. *Semin. Immunol.* 7, 255-266.
	Liu *et al.*, 1998, Engineering Src Family Protein Kinases with Unnatural Nucleotide Specificity. *Chemistry & Biology*, 5:91.
	Liu *et al.*, 1999, Structural Basis for Selective Inhibition of Src Family Kinases by PP1. *Chem. & Biol.* 6, 671-678.

Examiner:	Date Considered:

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) PTO Form 1449	Attorney Docket No. 051538-5001-01	Application No. not yet assigned Divisional of 09/480,997
	Applicants: Kevan M. SHOKAT	
	Filing Date: 01/15/02	Group Art Unit: 1651

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Liu *et al.*, 1998, A Molecular Gate which Controls Unnatural ATP Analogue Recognition by the Tyrosine Kinase v-Src. *Bioorganic & Medicinal Chemistry*, 6, 1219-1226.
		Mayer *et al.*, 1994, Mutagenic Analysis of the Roles of SH2 and SH3 Domains in Regulation of the Abl Tyrosine Kinase. *Mol. Cell. Bio.* 14: 2883.
		Mayer *et al.*,1992, Point Mutations in the Abl SH2 Domain Coordinately Impair Phosphotyrosine Binding *In Vitro*. *Mol. Cell. Bio.* 12:609.
		Measday *et al.*, 1994, The PCL2 (ORFD)-PHO85 Cyclin-Dependent Kinase Complex: A Cell Cycle Regulator in Yeast. *Science* 266, 1391-1395.
		Morgan, 1995, Principles of CDK Regulation. *Nature* 374, 131-134.
		Omura *et al.*, 1995, Staurosporine, a Potentially Important Gift from a Microorganism. *J. Antibiot.* 48, 535-548.
		Resh, 1998, Fyn, a Src Family Tyrosine Kinase. *Int. J. Biochem. & Cell Biol.* 30, 1159-1162.
		Shah *et al.*, 1997, Engineering Unnatural Nucleotide Specificity for Rous Sarcoma Virus Tyrosine Kinase to Uniquely Label its Direct Substrates. *Proc. Natl. Acad. Sci.*, 94: 3565.
		Tapley *et al.*, 1992, K252a Is a Selective Inhibitor of the Tyrosine Protein Kinase Activity of the *trk* Family of Oncogenes and Neurotrophin Receptors. *Oncogene* 7, 371-381.
		Taylor *et al.*, 1993, The Cell Cycle and C-Src. *Curr. Opin. Genet. Dev.* 3:26.
		Waksman *et al.*, 1993, Binding of a High Affinity Phosphotyrosyl Peptic to the Src SH2 Domain: Crystal Structures of the Complexed and Peptide-free Forms. *Cell*, 72:779.
		Waksman *et al.*, 1992, Crystal Structure of the Phosphotyrosine Recognition Domain SH2 of V-Src Complexed with Tyrosine-Phosphorylated Peptides. *Nature*, 358:646.
		Waltenberger *et al.*, 1999. A Dual Inhibitor of Platelet-Derived Growth Factor -Rec eptor and Src Kinases Activity Potently Interferes with Motogenic and Mitogenic Responses to PDGF in Vascular Smooth Muscle Cells. *Circ. Res.* 85, 12-21.
		Wood *et al.*, 1997, Design and Implementation of an Efficient Synthetic Approach to Furanosylated Indolocarbazoles: Total Synthesis of (+)- and (-)-K252a. *J. Am. Chem. Soc.* 119, 9641-9651.
		Wood *et al.*, 1999, Total Synthesis and Protein Kinase Activity of C(7) Methyl Derivatives of K252a. *Synthesis* SI, 1529-1533.
		Xu *et al.*, 1995, Substrate Specificities of the Insulin and Insulin-like Growth Factor 1 Receptor Tyrosine Kinase Catalytic Domains. *J. Biol. Chem.* 270:29825.
		Yu *et al.*, 1992, Solution Structure of the SH3 Domain of Src and Identification of its Ligand-Binding Site. *Science*, 258:1665.

Examiner:	Date Considered:

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.